The U.S. Food and Drug Administration has given the green light to Dupixent, a medication developed by Regeneron Pharmaceuticals (REGN, Financial) and Sanofi, for treating chronic spontaneous urticaria (CSU) in patients aged 12 and above. This approval is targeted at those who continue to experience symptoms despite using histamine-1 antihistamines.
Dupixent emerges as the first novel targeted therapy for CSU in over a decade, showcasing significant efficacy in reducing severe itching and unpredictable hives, which are hallmark symptoms of the disease. This FDA decision adds to Dupixent's portfolio, as it is now approved for seven chronic atopic conditions that share underlying type 2 inflammation. These conditions often occur alongside CSU, including atopic dermatitis and asthma, allowing patients a single treatment option for multiple atopic disorders.
This approval is set to benefit over 300,000 CSU patients in the United States who are inadequately managed by existing treatments. With limited therapeutic options previously available, Dupixent offers a promising alternative, addressing a significant gap in the treatment landscape for this population.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 25 analysts, the average target price for Regeneron Pharmaceuticals Inc (REGN, Financial) is $907.96 with a high estimate of $1,152.00 and a low estimate of $547.00. The average target implies an upside of 61.23% from the current price of $563.16. More detailed estimate data can be found on the Regeneron Pharmaceuticals Inc (REGN) Forecast page.
Based on the consensus recommendation from 28 brokerage firms, Regeneron Pharmaceuticals Inc's (REGN, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Regeneron Pharmaceuticals Inc (REGN, Financial) in one year is $906.31, suggesting a upside of 60.93% from the current price of $563.16. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Regeneron Pharmaceuticals Inc (REGN) Summary page.
